Sofosbuvir/daclatasvir
NS5B (RNA polymerase) inhibitor | |
| Clinical data | |
|---|---|
| Trade names | Darvoni,[1] Sovodak |
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | |
Daclatasvir/sofosbuvir (trade names Darvoni, Sovodak) is a two-drug combination for the treatment of
It is on the World Health Organization's List of Essential Medicines.[5]
Society and culture
This combination is produced by an Iranian company under the trade name of Sovodak.[6] The combination includes 400 mg sofosbuvir and 60 mg daclatasvir and has been used in clinical trials since 2015.[7][8][9] Sovodak was approved by the Iranian Food and Drug Administration in October 2015[10] and is currently marketed in Iran as the treatment of choice for all genotypes of hepatitis C as recommended by the national Iranian guideline for treating hepatitis C.[11]
Research
The similarities between the hepatitis C and SARS-CoV-2 virus has led some researches to investigate the effectiveness of sofosbuvir/daclatasvir against COVID-19. Three recently published studies have found this combination to be beneficial against COVID-19 although the findings require confirmation by larger studies.[12][13][14]
In October 2020, a meta-analysis found a significantly lower risk of all-cause mortality with the drug combination when given to hospitalized patients with COVID-19.[15]
References
- ^ "Home". Darvoni - Beacon Medicare Limited.
- PMID 27019602.
- ^ "Daklinza film-coated tablets – Summary of Product Characteristics (SPC) - (eMC)". Electronic Medicines Compendium. September 2016. Archived from the original on 2016-11-09.
- ^ "Sovaldi 400 mg film coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ Codrops. "Sovodak دارو". Archived from the original on 2019-07-03. Retrieved 2019-07-17.
- ^ Clinical trial number NCT02596880 for "Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics (SD100)" at ClinicalTrials.gov
- PMID 31504303.
- S2CID 210948579.
- ^ "Sofosbuvir". Iranian Food and Drug Administration. Archived from the original on 23 October 2017.
- ^ "Hepatitis Monthly | International Monthly Journal in the Field of Hepatology". Hepatitis Monthly. Retrieved 2019-07-17.
- S2CID 221182215.
- S2CID 221181054.
- S2CID 221180153.
- PMID 33063117.
